10 completed, 1 terminated, 1 withdrawn. 11 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 9, Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow AZD9977: new trials by email Literature Review of AZD9977 trials Research Report on AZD9977
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone Balcinrenone - Hepatic Impairment | Phase 1 | Completed | AstraZeneca | 30 | 2024-05-02 | 2024-11-12 |
| Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease AZD9977, Dapagliflozin - Heart Failure, Chronic Kidney Disease | Phase 2 | Completed | AstraZeneca | 153 | 2021-01-26 | 2024-11-19 |
| Absolute Bioavailability and ADME Study of [14C]AZD9977 in Healthy Male Subjects AZD9977 capsule 50 mg, [14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL), [14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq) - Cardiovascular Disease | Phase 1 | Completed | AstraZeneca | 8 | 2020-12-21 | 2021-03-09 |
| Study to Assess the Pharmacokinetics and Safety of AZD9977 in Participants With Renal Impairment AZD9977 - Renal Impairment | Phase 1 | Completed | AstraZeneca | 18 | 2020-06-22 | 2022-03-11 |
| A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers AZD9977, Itraconazole - Heart Failure With Preserved Ejection Fraction (HFpEF) | Phase 1 | Completed | AstraZeneca | 14 | 2019-02-22 | 2019-04-22 |
| A Study to Assess the Reaction of Body for Four Different Formulations of AZD9977 (Part A) and Influence of Food and Lower Dose of a Selected Formulation (Part B) in Healthy Male Subjects Treatment A, Treatment B, Treatment C - Heart Failure | Phase 1 | Completed | AstraZeneca | 12 | 2019-02-05 | 2021-04-19 |
| A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Japanese Healthy Participants With Single and Multiple Ascending Dose Administration AZD9977, Placebo - Heart Failure | Phase 1 | Completed | AstraZeneca | 28 | 2019-01-24 | 2019-05-10 |
| Study in HFpEF Patients to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium AZD9977, Spironolactone - Heart Failure | Phase 1 | Terminated | AstraZeneca | 68 | 2018-11-01 | 2020-05-01 |
| A Single Oral Dose Study to Evaluate Four Different Formulations of AZD9977 and the Effect of Food in Healthy Male Subjects AZD9977 Oral suspension (reference), AZD9977 capsule, AZD9977 ER capsule (fastvrate) - Healthy Volunteers | Phase 1 | Completed | AstraZeneca | 13 | 2018-03-28 | 2018-06-15 |
| Multiple-ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Healthy Male Subjects AZD9977, Placebo - Healthy Volunteers | Phase 1 | Completed | AstraZeneca | 27 | 2018-02-27 | 2018-06-21 |
| A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects AZD9977 immediate release (IR) oral suspension, AZD9977 extended release (ER) capsules [fast], AZD9977 extended release (ER) capsules [intermediate] - Pharmacokinetics, Healthy Male Subjects | Phase 1 | Withdrawn | AstraZeneca | 2015-11-01 | 2016-01-11 | |
| A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 After Single Ascending Doses to Healthy Males AZD9977, oral suspension, Placebo, oral suspension, AZD9977, oral solution - Safety, Tolerability | Phase 1 | Completed | AstraZeneca | 196 | 2015-07-01 | 2017-04-28 |
Heart Failure (7) · Cardiovascular Diseases (1) · Diabetes Mellitus, Type 2 (1) · Diabetic Nephropathies (1) · Renal Insufficiency (1) · Renal Insufficiency, Chronic (1)
AstraZeneca (12)
United Kingdom (8) · United States (4) · Bulgaria (2) · Czechia (2) · Poland (2) · Belgium (1) · Canada (1) · Denmark (1) · Germany (1) · Hungary (1) · India (1) · Italy (1) · Japan (1) · Lithuania (1) · Russia (1)
Pablo Forte Soto, MD, MSc, PhD (2) · Eric J Lawitz, M.D. (1) · John McMurray (1) · Juan C Rondon, M.D. (1) · Muna Albayaty, Dr. (1) · Muna Albayaty, MBChB, MSc, MFPM (1) · Ronald Goldwater (1) · Somasekhara Menakuru, MBBS, MS, MRCS, DPM (1) · Thomas C Marbury, M.D. (1)
2015 (2)